Ana C. Cabral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana C. Cabral has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Vitória Figueiredo
University of Coimbra
10 shared publications - Margarida Castel-Branco
University of Coimbra
10 shared publications - Marta Lavrador
University of Lisbon
10 shared publications - Fernando Fernandez-Llimos
University of Porto
9 shared publications - Manuel Teixeira Veríssimo
Faculty of Medicine, University of Coimbra, Coimbra, Portugal
3 shared publications - Maria Margarida Caramona
Pharmacology and Pharmaceutical Care Laboratory, Faculty of Pharmacy, University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal.
2 shared publications
Latest Publications
- 9 November 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- p. 1-16
Current and emerging measures and methods for evaluating medication adherence behaviors
Medication adherence is a key determinant of treatment effectiveness and health outcomes, yet it remains a major challenge in clinical practice and research. As dynamic and multidimensional behavior influenced by cognitive, emotional, and contextual factors, adherence cannot be fully captured by a single measure. This complexity is further amplified in real-world settings characterized by multimorbidity and polypharmacy. This review examines current and emerging methods for measuring medication adherence. It considers the data sources and computation procedures required. These methods were classified into self-report instruments, electronic monitoring systems, administrative pharmacy claims, and group-based trajectory modeling. It discusses their conceptual basis, strengths, and limitations, highlighting how different methods capture distinct dimensions of adherence behavior. No single method represents a universal gold standard, and adherence measures are not interchangeable. Selection should be guided by the research objective, whether focused on exposure, determinants, or outcomes. Future advances will depend on integrating complementary methods and adopting longitudinal approaches to better reflect the dynamic nature of adherence and support more effective interventions.
- 9 November 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- p. 1-16
Current and emerging measures and methods for evaluating medication adherence behaviors
Medication adherence is a key determinant of treatment effectiveness and health outcomes, yet it remains a major challenge in clinical practice and research. As dynamic and multidimensional behavior influenced by cognitive, emotional, and contextual factors, adherence cannot be fully captured by a single measure. This complexity is further amplified in real-world settings characterized by multimorbidity and polypharmacy. This review examines current and emerging methods for measuring medication adherence. It considers the data sources and computation procedures required. These methods were classified into self-report instruments, electronic monitoring systems, administrative pharmacy claims, and group-based trajectory modeling. It discusses their conceptual basis, strengths, and limitations, highlighting how different methods capture distinct dimensions of adherence behavior. No single method represents a universal gold standard, and adherence measures are not interchangeable. Selection should be guided by the research objective, whether focused on exposure, determinants, or outcomes. Future advances will depend on integrating complementary methods and adopting longitudinal approaches to better reflect the dynamic nature of adherence and support more effective interventions.
- Open Access
- 26 October 2026
- Published by Sociedad Española de Farmacia Clínica, Familiar y Comunitaria (SEFAC) in Farmacéuticos Comunitarios
- Vol. 19 (1)
Addressing medication complexity in outpatient care: are Multicompartment Compliance Aids enough?
Introduction: Medication regimen complexity contributes to unintentional non-adherence, particularly in older adults and patients with chronic conditions. Multicompartment compliance aids (MCAs) are widely used to support adherence, but their real-world effectiveness in outpatients with high regimen complexity remains uncertain. Aim: To evaluate the suitability of MCAs in outpatients with high medication regimen complexity using the Medication Regimen Complexity Index (MRCI). Method: A cross-sectional study was conducted in five community pharmacies in Central Portugal (January–July 2023). Adults (>18 years), autonomous in medication management, were included. Medication data were collected through semi-structured interviews and analyzed using the MRCI. Each medicine was assessed for MCA suitability according to national and international guidelines. Associations between MRCI and MCA feasibility were analyzed using appropriate statistical tests (p < 0.05). Results: Among 189 participants (64.6% female; median age 72 years), 94.7% were under polypharmacy and 23.8% under hyper-polypharmacy. The median number of medications was 7, and the median MRCI score was 26, with 51.9% at or above this threshold. MRCI strongly correlated with medication number (ρ = 0.918; p < 0.001). Although 79.4% of regimens were eligible for MCA inclusion, only 42.7% of eligible regimens were fully accommodated. Patients with lower MRCI scores had a 3.8-fold higher likelihood of full MCA inclusion (72.7% vs. 19.1%; χ² = 43.5; p < 0.001). Conclusion: MCAs alone may be insufficient for patients with high regimen complexity. Combining MCA use with structured medication reviews and regimen simplification may improve adherence.
- 26 October 2026
- Published by Sociedad Española de Farmacia Clínica, Familiar y Comunitaria (SEFAC) in Farmacéuticos Comunitarios
- Vol. 19 (1)
Open AccessAddressing medication complexity in outpatient care: are Multicompartment Compliance Aids enough?
Introduction: Medication regimen complexity contributes to unintentional non-adherence, particularly in older adults and patients with chronic conditions. Multicompartment compliance aids (MCAs) are widely used to support adherence, but their real-world effectiveness in outpatients with high regimen complexity remains uncertain. Aim: To evaluate the suitability of MCAs in outpatients with high medication regimen complexity using the Medication Regimen Complexity Index (MRCI). Method: A cross-sectional study was conducted in five community pharmacies in Central Portugal (January–July 2023). Adults (>18 years), autonomous in medication management, were included. Medication data were collected through semi-structured interviews and analyzed using the MRCI. Each medicine was assessed for MCA suitability according to national and international guidelines. Associations between MRCI and MCA feasibility were analyzed using appropriate statistical tests (p < 0.05). Results: Among 189 participants (64.6% female; median age 72 years), 94.7% were under polypharmacy and 23.8% under hyper-polypharmacy. The median number of medications was 7, and the median MRCI score was 26, with 51.9% at or above this threshold. MRCI strongly correlated with medication number (ρ = 0.918; p < 0.001). Although 79.4% of regimens were eligible for MCA inclusion, only 42.7% of eligible regimens were fully accommodated. Patients with lower MRCI scores had a 3.8-fold higher likelihood of full MCA inclusion (72.7% vs. 19.1%; χ² = 43.5; p < 0.001). Conclusion: MCAs alone may be insufficient for patients with high regimen complexity. Combining MCA use with structured medication reviews and regimen simplification may improve adherence.
- Open Access
- 27 August 2024
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (5) , 1243
Correction: Development and validation of a Medication Adherence Universal Questionnaire: the MAUQ
- 27 August 2024
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (5) , 1243
Open AccessCorrection: Development and validation of a Medication Adherence Universal Questionnaire: the MAUQ
- Open Access
- 27 December 2023
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (2) , 411-420
Discrepancies among equations to estimate the glomerular filtration rate for drug dosing decision making in aged patients: a cross sectional study
Background: Patients often require adjustments to drug doses due to impaired renal function. Glomerular filtration rate (GFR) estimation using various equations can result in discrepancies, potentially leading to different dose adjustment recommendations. Aim: To determine the clinical significance of discrepancies observed between different equations used to estimate GFR for drug dose adjustments in a real-world group of patients over 65 years in primary care. Method: The Cockcroft–Gault (CG), Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Berlin Initiative Study 1 equations were applied to estimate GFR in a group of patients over 65 years old attending a primary care center. Results were compared using Bland–Altman plots, and limits of agreement (LoA) and overall bias were calculated. Regression analyses were conducted to identify the null difference GFR and the slope of differences for each pairwise comparison. Results: A total of 1886 patients were analyzed. Differences between patient-adjusted and body surface area (BSA)-normalized versions of the equations were not clinically relevant for dose adjustments, with LoAs below 20 mL/min. However, discrepancies among the original versions of several equations presented LoAs over 30 mL/min. Greater differences were found between CG and MDRD or CKD-EPI equations. Conclusion: Clinically relevant differences in GFR estimation were observed among different equations, potentially impacting drug dose adjustments. However, discrepancies were not considered significant when comparing patient-adjusted and BSA-normalized versions of the equations, particularly for patients with BSA close to the average.
- 27 December 2023
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (2) , 411-420
Open AccessDiscrepancies among equations to estimate the glomerular filtration rate for drug dosing decision making in aged patients: a cross sectional study
Background: Patients often require adjustments to drug doses due to impaired renal function. Glomerular filtration rate (GFR) estimation using various equations can result in discrepancies, potentially leading to different dose adjustment recommendations. Aim: To determine the clinical significance of discrepancies observed between different equations used to estimate GFR for drug dose adjustments in a real-world group of patients over 65 years in primary care. Method: The Cockcroft–Gault (CG), Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Berlin Initiative Study 1 equations were applied to estimate GFR in a group of patients over 65 years old attending a primary care center. Results were compared using Bland–Altman plots, and limits of agreement (LoA) and overall bias were calculated. Regression analyses were conducted to identify the null difference GFR and the slope of differences for each pairwise comparison. Results: A total of 1886 patients were analyzed. Differences between patient-adjusted and body surface area (BSA)-normalized versions of the equations were not clinically relevant for dose adjustments, with LoAs below 20 mL/min. However, discrepancies among the original versions of several equations presented LoAs over 30 mL/min. Greater differences were found between CG and MDRD or CKD-EPI equations. Conclusion: Clinically relevant differences in GFR estimation were observed among different equations, potentially impacting drug dose adjustments. However, discrepancies were not considered significant when comparing patient-adjusted and BSA-normalized versions of the equations, particularly for patients with BSA close to the average.
- Open Access
- 17 June 2023
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (4) , 999-1006
Development and validation of a Medication Adherence Universal Questionnaire: the MAUQ
Background: Different questionnaires assess self-reported medication adherence and others quantify aspects of patients attitudes towards medication, but not together in a single instrument. Gathering these two aspects in a single instrument could reduce patients survey burden. Aim: The aim of this study was to develop the Medication Adherence Universal Questionnaire (MAUQ) using the Maastricht Utrecht Adherence in Hypertension short version (MUAH-16) factorial structure as the hypothesized model. Method: A multistep process started with the modification of the MUAH-16 to obtain the MAUQ. Patients using at least one antihypertensive medicine were recruited. The two questionnaires, the MUAH-16 and MAUQ, were applied. A confirmatory factor analysis (CFA) was performed using the initial MUAH-16 s-order 4-factor model. An additional bifactor model with four uncorrelated factors and an overall score was tested. The comparative fit index (CFI), root mean square error of approximation (RMSEA) with confidence intervals (CIs), and standardized root mean squared residual (SRMR) were used to assess both models. Results: A sample of 300 hypertensive patients completed the instruments. The CFA with the second-order 4-factor solution resulted in similar results for the MUAH-16 and MAUQ: CFIs of 0.934 and 0.930, RMSEAs of 0.043 [CI 0.030–0.056] and 0.045 [CI 0.031–0.057] and SRMRs of 0.060 and 0.061, respectively. The CFA with the bifactor model showed slightly better results for both the MUAH-16 and MAUQ: CFIs of 0.974 and 0.976, RMSEAs of 0.030 [CI 0.005–0.046] and 0.028 [CI 0.001–0.044], and SRMRs of 0.043 and 0.044, respectively. Conclusion: CFA demonstrated that the MAUQ presented a better fit to both models than the MUAH-16, obtaining a robust universal free instrument to assess medicine-taking behaviour and four medicine beliefs components.
- 17 June 2023
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (4) , 999-1006
Open AccessDevelopment and validation of a Medication Adherence Universal Questionnaire: the MAUQ
Background: Different questionnaires assess self-reported medication adherence and others quantify aspects of patients attitudes towards medication, but not together in a single instrument. Gathering these two aspects in a single instrument could reduce patients survey burden. Aim: The aim of this study was to develop the Medication Adherence Universal Questionnaire (MAUQ) using the Maastricht Utrecht Adherence in Hypertension short version (MUAH-16) factorial structure as the hypothesized model. Method: A multistep process started with the modification of the MUAH-16 to obtain the MAUQ. Patients using at least one antihypertensive medicine were recruited. The two questionnaires, the MUAH-16 and MAUQ, were applied. A confirmatory factor analysis (CFA) was performed using the initial MUAH-16 s-order 4-factor model. An additional bifactor model with four uncorrelated factors and an overall score was tested. The comparative fit index (CFI), root mean square error of approximation (RMSEA) with confidence intervals (CIs), and standardized root mean squared residual (SRMR) were used to assess both models. Results: A sample of 300 hypertensive patients completed the instruments. The CFA with the second-order 4-factor solution resulted in similar results for the MUAH-16 and MAUQ: CFIs of 0.934 and 0.930, RMSEAs of 0.043 [CI 0.030–0.056] and 0.045 [CI 0.031–0.057] and SRMRs of 0.060 and 0.061, respectively. The CFA with the bifactor model showed slightly better results for both the MUAH-16 and MAUQ: CFIs of 0.974 and 0.976, RMSEAs of 0.030 [CI 0.005–0.046] and 0.028 [CI 0.001–0.044], and SRMRs of 0.043 and 0.044, respectively. Conclusion: CFA demonstrated that the MAUQ presented a better fit to both models than the MUAH-16, obtaining a robust universal free instrument to assess medicine-taking behaviour and four medicine beliefs components.
- Open Access
- 14 March 2022
- Published by JCFCorp SG PTE LTD in Pharmacy Practice
- Vol. 20 (2) , 01-08
Pharmacist-led medication reconciliation on admission to an acute psychiatric hospital unit
Background: Therapy management in patients suffering from mental health disorders is complex and the risks derived from changes or interruptions of treatment should not be ignored. Medication reconciliation in psychiatry may reduce medication errors and promote patient safety during transitions of care. Objective: To identify the influence of complementary information sources in the construction of the best possible medication history, and to ascertain the potential clinical impact of discrepancies identified in a medication reconciliation service. Methods: An observational study was conducted in an acute mental hospital unit, with a further validation in an internal medicine unit. Adult patients taking at least one medicine admitted in the unit were included. Patients/caregivers were interviewed upon admission and the information gathered was compared with hospital medical and shared electronic medical records. Once the best possible medication history was gathered, therapeutic information was reconciled against the prescription on admission to identify discrepancies. Potential clinical impact of medication errors was classified using the International Safety Classification. Results: During the study period, 148 patients were admitted, 50.7% females, mean age 54.6 years (SD=16.3). Collaboration of a caregiver was a needed in 74% of the interviews. In total, 1,147 drugs were considered to obtain patients’ best possible medication history. After reconciliation, 560 clinically sound intentional discrepancies were identified and 359 discrepancies required further clarification from prescribers: 84.12% “drug omission”, 5.57% “drug substitution”, 6.96% “dose change”, and 3.34% “dosage frequency change”. Potential clinical impact of these medication discrepancies was classified as: 95 mild, 100 moderate, and 29 severe medication errors. Conclusion: About 1 in three intentional discrepancies observed in a pharmacists-led medication reconciliation service required further clarification from prescribers, being 80% of them unintentional discrepancies. Results highlight the importance of the caregiver as source of information for the psychiatric patient, the relevance of analyzing shared electronic health records until 6 months before, and the need to use hospital medical records efficiently. Additionally, 29 discrepancies were classified as errors with potentially severe clinical impact. A medication reconciliation service is concluded to be feasible and necessary in a mental health unit. Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology
- 14 March 2022
- Published by JCFCorp SG PTE LTD in Pharmacy Practice
- Vol. 20 (2) , 01-08
Open AccessPharmacist-led medication reconciliation on admission to an acute psychiatric hospital unit
Background: Therapy management in patients suffering from mental health disorders is complex and the risks derived from changes or interruptions of treatment should not be ignored. Medication reconciliation in psychiatry may reduce medication errors and promote patient safety during transitions of care. Objective: To identify the influence of complementary information sources in the construction of the best possible medication history, and to ascertain the potential clinical impact of discrepancies identified in a medication reconciliation service. Methods: An observational study was conducted in an acute mental hospital unit, with a further validation in an internal medicine unit. Adult patients taking at least one medicine admitted in the unit were included. Patients/caregivers were interviewed upon admission and the information gathered was compared with hospital medical and shared electronic medical records. Once the best possible medication history was gathered, therapeutic information was reconciled against the prescription on admission to identify discrepancies. Potential clinical impact of medication errors was classified using the International Safety Classification. Results: During the study period, 148 patients were admitted, 50.7% females, mean age 54.6 years (SD=16.3). Collaboration of a caregiver was a needed in 74% of the interviews. In total, 1,147 drugs were considered to obtain patients’ best possible medication history. After reconciliation, 560 clinically sound intentional discrepancies were identified and 359 discrepancies required further clarification from prescribers: 84.12% “drug omission”, 5.57% “drug substitution”, 6.96% “dose change”, and 3.34% “dosage frequency change”. Potential clinical impact of these medication discrepancies was classified as: 95 mild, 100 moderate, and 29 severe medication errors. Conclusion: About 1 in three intentional discrepancies observed in a pharmacists-led medication reconciliation service required further clarification from prescribers, being 80% of them unintentional discrepancies. Results highlight the importance of the caregiver as source of information for the psychiatric patient, the relevance of analyzing shared electronic health records until 6 months before, and the need to use hospital medical records efficiently. Additionally, 29 discrepancies were classified as errors with potentially severe clinical impact. A medication reconciliation service is concluded to be feasible and necessary in a mental health unit. Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology
- Open Access
- 2 November 2021
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 34 (11) , 797
Intensive Care for COVID-19 Patients with Severe Mental Illness: A Call for Debate
Intensive Care for COVID-19 Patients with Severe Mental Illness: A Call for Debate
- 2 November 2021
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 34 (11) , 797
Open AccessIntensive Care for COVID-19 Patients with Severe Mental Illness: A Call for Debate
Intensive Care for COVID-19 Patients with Severe Mental Illness: A Call for Debate
- 29 August 2020
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 43 (1) , 128-136
Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients
Background Several anticholinergic scales and equations to evaluate the anticholinergic burden have been previously created. Association of these instruments with the anticholinergic outcomes are usually estimated by means of hypothesis contrast tests, which ignore the size of the association effect. Objective To evaluate the effect size of the associations between the scores on cumulative anticholinergic burden instruments with peripheral or central anticholinergic adverse outcomes in older patients. Setting Internal medicine ward of a Tertiary University Hospital. Methods A case–control study was conducted in patients over 65 years who were admitted to two internal medicine wards of a Portuguese university hospital. The Anticholinergic Drug Scale, Anticholinergic Risk Scale, Anticholinergic Cognitive Burden scale and Drug Burden Index were used to calculate the patients’ anticholinergic burden. Peripheral (dry mouth—swab technique; dry eye—Schirmer test) and central (falls and cognitive impairment—Mini-Mental State Examination) anticholinergic adverse outcomes were investigated. The Barthel Index was used to assess overall physical functionality. The Mann–Whitney test was used to evaluate probabilistic differences in the anticholinergic scores between case and control individuals. To establish the effect size of the associations, the area under the curve of the receiver operating characteristics curve was calculated. Main outcome measure Anticholinergic adverse effects. Results A total of 250 patients (mean age 81.67 years, standard deviation 7.768; 50% females) were included. In total, 148 patients (59.2%) presented with dry mouth, 85 (34%) with dry eye, 141 (56.4%) with impaired functionality, 44 (17.6%) with a history of falls and 219 (87.6%) with cognitive impairment. Significant differences (p < 0.05) were obtained for the majority of the associations between Anticholinergic Drug Scale, Anticholinergic Risk Scale, Anticholinergic Cognitive Burden and Drug Burden Index and adverse effects. Conversely, the effect sizes of these associations ranged from “fail” (area under the curve 0.5 to 0.6) to “fair” (area under the curve 0.7 to 0.8). Conclusion Although significant differences in the scores of anticholinergic burden instruments and adverse outcomes may exist, the effect sizes of these associations ranged from ‘fail’ to ‘fair’, which limits their utility in preventing anticholinergic adverse outcomes with medication review interventions.
- 29 August 2020
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 43 (1) , 128-136
Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients
Background Several anticholinergic scales and equations to evaluate the anticholinergic burden have been previously created. Association of these instruments with the anticholinergic outcomes are usually estimated by means of hypothesis contrast tests, which ignore the size of the association effect. Objective To evaluate the effect size of the associations between the scores on cumulative anticholinergic burden instruments with peripheral or central anticholinergic adverse outcomes in older patients. Setting Internal medicine ward of a Tertiary University Hospital. Methods A case–control study was conducted in patients over 65 years who were admitted to two internal medicine wards of a Portuguese university hospital. The Anticholinergic Drug Scale, Anticholinergic Risk Scale, Anticholinergic Cognitive Burden scale and Drug Burden Index were used to calculate the patients’ anticholinergic burden. Peripheral (dry mouth—swab technique; dry eye—Schirmer test) and central (falls and cognitive impairment—Mini-Mental State Examination) anticholinergic adverse outcomes were investigated. The Barthel Index was used to assess overall physical functionality. The Mann–Whitney test was used to evaluate probabilistic differences in the anticholinergic scores between case and control individuals. To establish the effect size of the associations, the area under the curve of the receiver operating characteristics curve was calculated. Main outcome measure Anticholinergic adverse effects. Results A total of 250 patients (mean age 81.67 years, standard deviation 7.768; 50% females) were included. In total, 148 patients (59.2%) presented with dry mouth, 85 (34%) with dry eye, 141 (56.4%) with impaired functionality, 44 (17.6%) with a history of falls and 219 (87.6%) with cognitive impairment. Significant differences (p < 0.05) were obtained for the majority of the associations between Anticholinergic Drug Scale, Anticholinergic Risk Scale, Anticholinergic Cognitive Burden and Drug Burden Index and adverse effects. Conversely, the effect sizes of these associations ranged from “fail” (area under the curve 0.5 to 0.6) to “fair” (area under the curve 0.7 to 0.8). Conclusion Although significant differences in the scores of anticholinergic burden instruments and adverse outcomes may exist, the effect sizes of these associations ranged from ‘fail’ to ‘fair’, which limits their utility in preventing anticholinergic adverse outcomes with medication review interventions.
- 29 October 2019
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 41 (6) , 1562-1569
Patients’ clinical information requirements to apply the STOPP/START criteria
Background The STOPP/START criteria are an explicit tool to detect potentially inappropriate medications (PIMs). Patient clinical information may not be available in all settings. Objective To identify patient clinical information needed to apply the STOPP/START criteria. Setting: Four nursing homes in Portugal. Methods First, a theoretical analysis was performed to identify the patient information required to apply the STOPP/START criteria (v2), according to the following categories: patients’ current medication, medication history (previous medication and duration), medical records (current and past medical conditions), and laboratory test results. A verification of the information requirements was conducted through a cross-sectional study on a nursing home population with patients over 65 years old. Patients’ medical records were appraised to extract only demographic data and current medication profiles. Main outcome measure Information requirements of STOPP/START. Results For only 29 of the 81 STOPP criteria and 1 of the 34 START criteria, a judgement could be made with only the information in the patient’s medication profile. 52 STOPP and 33 START criteria require additional information, (i.e. duration of therapy, previous medication, current and past medical conditions, and laboratory data). The 208 evaluated persons (87 years; 68.75% female) used 1770 medications, with 989 (55.9%) potentially involved in 1629 STOPP criteria. Sufficient information to judge STOPP criteria was available for only 529 (32.5%) potential STOPP criteria situations, with a positive identification of a STOPP PIM in 397 instances (75.0%). Conclusions Although STOPP/START criteria can be considered a high-level tool to identify PIMs, their use may be compromised in scenarios where access to patients’ clinical information is limited.
- 29 October 2019
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 41 (6) , 1562-1569
Patients’ clinical information requirements to apply the STOPP/START criteria
Background The STOPP/START criteria are an explicit tool to detect potentially inappropriate medications (PIMs). Patient clinical information may not be available in all settings. Objective To identify patient clinical information needed to apply the STOPP/START criteria. Setting: Four nursing homes in Portugal. Methods First, a theoretical analysis was performed to identify the patient information required to apply the STOPP/START criteria (v2), according to the following categories: patients’ current medication, medication history (previous medication and duration), medical records (current and past medical conditions), and laboratory test results. A verification of the information requirements was conducted through a cross-sectional study on a nursing home population with patients over 65 years old. Patients’ medical records were appraised to extract only demographic data and current medication profiles. Main outcome measure Information requirements of STOPP/START. Results For only 29 of the 81 STOPP criteria and 1 of the 34 START criteria, a judgement could be made with only the information in the patient’s medication profile. 52 STOPP and 33 START criteria require additional information, (i.e. duration of therapy, previous medication, current and past medical conditions, and laboratory data). The 208 evaluated persons (87 years; 68.75% female) used 1770 medications, with 989 (55.9%) potentially involved in 1629 STOPP criteria. Sufficient information to judge STOPP criteria was available for only 529 (32.5%) potential STOPP criteria situations, with a positive identification of a STOPP PIM in 397 instances (75.0%). Conclusions Although STOPP/START criteria can be considered a high-level tool to identify PIMs, their use may be compromised in scenarios where access to patients’ clinical information is limited.